Emergent Biosolutions Inc.
Could not find a ticker for this position, may be a filing error
A specialty biopharmaceutical company that makes medicines to protect against biological threats and opioid overdoses. Its best-known products include BioThrax, a vaccine against anthrax, and NARCAN, a nasal spray that reverses opioid overdoses and became the first naloxone product sold over the counter without a prescription. Founded in 1998 as BioPort, the company took over Michigan's anthrax vaccine facilities and later renamed itself Emergent BioSolutions, a nod to its role in helping people emerge from public health emergencies.
2.875% Convertible Senior Notes due 2021
Granted 470.2K · Bought 60.0K
Granted 324.6K
Granted 162.6K · Sold 30.6K
Granted 15.0K
Granted 177.6K
Granted 192.1K
Granted 166.8K
Granted 162.6K · Sold 4.0K
Granted 195.8K · Sold 35.0K
Granted 77.2K
Granted 51.8K
Granted 195.8K · Sold 66.1K
Granted 102.9K · Sold 22.0K
Granted 77.2K · Sold 14.3K
Granted 77.2K · Sold 22.3K
Granted 77.2K · Sold 23.3K
Granted 77.2K · Sold 47.2K
Granted 30.4K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Papa Joseph CPresident and CEO, Director · 4 transactions | — | 493.2K | 470.2K | 60.0K | — |
| Lindahl Richard SEVP, Chief Financial Officer · 18 transactions | +202.3% | 374.1K | 324.6K | — | — |
| Glessner ColeenEVP, Quality & Ethics, and CPL · 17 transactions | +50.2% | 202.2K | 162.6K | — | 30.6K |
| Fox Jennifer LynneEVP, Ext Aff, GC, Corp Sec · 6 transactions | +4% | 186.4Kas of Jul 2024 | 15.0K | — | — |
| Hartzel WilliamSVP, Bioservices · 17 transactions | +416.6% | 185.6K | 177.6K | — | — |
| Lowry Simon CSVP, R&D, CMO · 5 transactions | — | 177.9K | 192.1K | — | — |
| Perl JessicaSVP, General Counsel, Corp Sec · 5 transactions | — | 165.3K | 166.8K | — | — |
| Williams Paul AnthonySVP, Products Business · 17 transactions | +520.1% | 162.1K | 162.6K | — | 4.0K |
| Fowler Neal FranklinDirector · 5 transactions | — | 160.8K | 195.8K | — | 35.0K |
| Harsanyi ZsoltChairman, Director · 3 transactions | +107.3% | 149.1K | 77.2K | — | — |
| Sullivan Louis WDirector · 2 transactions | +59.4% | 139.1Kas of Apr 2025 | 51.8K | — | — |
| DeGolyer Donald WDirector · 9 transactions | — | 130.7K | 195.8K | — | 66.1K |
| Richard RonaldDirector · 7 transactions | +130.5% | 123.8K | 102.9K | — | 22.0K |
| White Marvin LDirector · 4 transactions | +123.4% | 113.8K | 77.2K | — | 14.3K |
| Dayal Sujata TyagiDirector · 6 transactions | +122.2% | 101.5K | 77.2K | — | 22.3K |
| Katkin KeithDirector · 5 transactions | +126.9% | 96.3K | 77.2K | — | 23.3K |
| Zoon Kathryn CDirector · 10 transactions | +62.1% | 81.0K | 77.2K | — | 47.2K |
| Fowler John D JrDirector · 2 transactions | — | 30.4K | 30.4K | — | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 3 years: -204.8K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.